Clinical Trial Update: High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating high-dose Imatinib in relapsed or refractory c-Kit–positive acute myeloid leukemia. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Nantes University Hospital | Conditions: AML | Phase 2 | Status: COMPLETED